Welcome to CDC Stacks | Incidence of End-Stage Renal Disease among Newly Diagnosed Systemic Lupus Erythematosus Patients: The Georgia Lupus Registry - 37867 | CDC Public Access
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All Simple Search
Advanced Search
Incidence of End-Stage Renal Disease among Newly Diagnosed Systemic Lupus Erythematosus Patients: The Georgia Lupus Registry
Filetype[PDF - 575.92 KB]


Details:
  • Pubmed ID:
    26239749
  • Pubmed Central ID:
    PMC4740266
  • Funding:
    KL2-TR-000455/TR/NCATS NIH HHS/United States
    CDC-RFA-DP08-806/DP/NCCDPHP CDC HHS/United States
    R01 AR065493/AR/NIAMS NIH HHS/United States
    KL2 TR000455/TR/NCATS NIH HHS/United States
    PA03022/PHS HHS/United States
    R01-AR-065493/AR/NIAMS NIH HHS/United States
    R24 MD008077/MD/NIMHD NIH HHS/United States
    U01-DP-005119/DP/NCCDPHP CDC HHS/United States
    UL1-TR-000454/TR/NCATS NIH HHS/United States
    1R24MD008077-01/MD/NIMHD NIH HHS/United States
    CC999999/Intramural CDC HHS/United States
    UL1 TR000454/TR/NCATS NIH HHS/United States
    U01 DP005119/DP/NCCDPHP CDC HHS/United States
    R24MD008077-01/MD/NIMHD NIH HHS/United States
  • Document Type:
  • Collection(s):
  • Description:
    Objective

    To estimate and identify factors associated with incidence of all-cause end-stage renal disease (ESRD) among newly diagnosed systemic lupus erythematosus (SLE) patients.

    Methods

    Data from a national registry of treated ESRD were linked to data from a lupus registry of SLE patients who were newly diagnosed and living in Atlanta, Georgia, in 2002-2004 (median follow-up, 7.8 years). Cumulative incidence and incidence rates (ESRD treatment initiations per 1000 patient-years) were calculated, and age- and race-adjusted Poisson models were used to calculate incidence rate ratios (IRRs).

    Results

    Among 344 newly diagnosed SLE patients, 29 initiated ESRD over 2603.8 years of follow-up. Incidence rates were 13.8 (95% CI, 9.4-20.3) and 3.3 (95% CI, 0.8-13.0) per 1000 patient-years among black and white patients, respectively; corresponding 5-year cumulative incidence was 6.4% and 2.5%. Lupus nephritis documented prior to 2005, which occurred in 80% of those who progressed to ESRD, was the strongest risk factor for incident ESRD (IRR=6.7, 95% CI, 2.7-16.8; incidence rate=27.6 per 1000 patient-years). Results suggested that patients who were black vs. white (IRR=3.9, 95% CI, 0.9-16.4) or <18 years (vs. ≥30 years) at diagnosis (IRR=2.1, 95% CI, 0.9-5.3) may be more likely to progress to ESRD, but incidence did not differ by sex or other characteristics.

    Conclusion

    Incidence of all-cause ESRD among patients with a recent diagnosis of SLE is high in Georgia. Interventions to decrease ESRD incidence among newly diagnosed SLE patients should target young and black patients as well as patients with lupus nephritis.